(NASDAQ: ATYR) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Atyr Pharma's earnings in 2025 is -$75,122,000.On average, 12 Wall Street analysts forecast ATYR's earnings for 2025 to be -$82,387,162, with the lowest ATYR earnings forecast at -$90,265,287, and the highest ATYR earnings forecast at -$72,020,176. On average, 12 Wall Street analysts forecast ATYR's earnings for 2026 to be -$62,113,727, with the lowest ATYR earnings forecast at -$78,742,059, and the highest ATYR earnings forecast at -$36,010,088.
In 2027, ATYR is forecast to generate -$51,825,131 in earnings, with the lowest earnings forecast at -$80,662,597 and the highest earnings forecast at -$25,721,491.